Brevan Howard Capital Management’s Sana Biotechnology SANA Stock Holding History

Brevan Howard Capital Management’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$183K	Sell	52,545 -265	-0.5%	-$854	﹤0.01%	1922
2026 Q1	$152K	Sell	52,810 -17,797	-25%	-$70.1K	﹤0.01%	1965
2025 Q4	$287K	Buy	+70,607	New	+$316K	﹤0.01%	1395
2025 Q3	–	Sell	-260,723	Closed	-$712K	–	2238
2025 Q2	$712K	Buy	260,723 +120,016	+85%	+$248K	﹤0.01%	1217
2025 Q1	$236K	Buy	140,707 +67,081	+91%	+$188K	﹤0.01%	932
2024 Q4	$120K	Buy	+73,626	New	+$220K	﹤0.01%	950
2024 Q3	–	Sell	-46,296	Closed	-$253K	–	1398
2024 Q2	$253K	Buy	+46,296	New	+$369K	﹤0.01%	827

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Brevan Howard Capital Management's SANA Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Sana Biotechnology (SANA) stake by 0.5% in Q2 2026, selling an estimated $854 and leaving 52,545 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #1922.

Brevan Howard Capital Management first reported a position in SANA in Q2 2024 and has held it in 7 quarters since. The position peaked at $712K in Q2 2025. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

Brevan Howard Capital Management held 52,545 shares of Sana Biotechnology worth $183K as of Q2 2026.
Brevan Howard Capital Management sold 265 Sana Biotechnology shares in Q2 2026, an estimated $854.
Sana Biotechnology made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1922 holding.
Brevan Howard Capital Management first reported a position in Sana Biotechnology in Q2 2024 and has held it in 7 quarters since.
Brevan Howard Capital Management's Sana Biotechnology position peaked at $712K in Q2 2025.
211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.